Tyrosine 500mg capsules
Requires a prescription from a doctor or prescriber
Tyrosine is a non-essential amino acid.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Tyrosine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tyrosine
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(14)
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 47 · 1985–2026
Showing the 50 most relevant studies, sorted by most relevant.
Z. Du, C. Lovly
Molecular Cancer, 2018
Simar Pal Singh, Floris Dammeijer, R. Hendriks
Molecular Cancer, 2018
Guoshuang Shen, F. Zheng, Dengfeng Ren, et al.
Journal of Hematology & Oncology, 2018
G. Ferrer-Sueta, Nicolás Campolo, M. Trujillo, et al.
Chemical reviews, 2018
S. Bartesaghi, R. Radi
Redox Biology, 2017
Liling Huang, Shiyu Jiang, Yuankai Shi
Journal of Hematology & Oncology, 2020
Qinlian Jiao, Lei Bi, Yidan Ren, et al.
Molecular Cancer, 2018
J. Barros, R. Dixon
Trends in plant science, 2019
Kashizaki F, Watanabe S, Orii R, et al.
2026
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Proto-Oncogene Proteins
Ma C, Lu Y, Li J, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Tyrosine is produced in cells by hydroxylating the essential amino acid phenylalanine.
Food interactions
None known
Human targets
4 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Metabolism
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medicines. Always consult a healthcare professional.
Showing 1 of 1 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
Positively regulates the regression of retinal hyaloid vessels during postnatal development (By similarity)
PMID:25533949
Also acts as a positive regulator of poly-ADP-ribosylation in the nucleus, independently of its tyrosine--tRNA ligase activity .
PMID:25533949
Activity is switched upon resveratrol-binding: resveratrol strongly inhibits the tyrosine--tRNA ligase activity and promotes relocalization to the nucleus, where YARS1 specifically stimulates the poly-ADP-ribosyltransferase activity of PARP1 PMID:25533949
Has much lower affinity and transaminase activity towards phenylalanine
Proteins that transport this drug across cell membranes
PMID:16887882 PMID:18337592 PMID:20628049 PMID:23550058 PMID:26426690 PMID:27805744 PMID:31436139
Acts as an important mediator of thyroid hormone transport, especially T3, through the blood-brain barrier (Probable) PMID:28526555
PMID:11827462 PMID:18337592 PMID:28754537
Mediates both uptake and efflux of 3,5,3'-triiodothyronine (T3) and 3,5,3',5'-tetraiodothyronine (T4) with high affinity, suggesting a role in the homeostasis of thyroid hormone levels .
PMID:18337592
Responsible for low affinity bidirectional transport of the aromatic amino acids, such as phenylalanine, tyrosine, tryptophan and L-3,4-dihydroxyphenylalanine (L-dopa) .
PMID:11827462 PMID:28754537
Plays an important role in homeostasis of aromatic amino acids (By similarity)
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Involved compounds
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tyrosine
Additional database identifiers
Drugs Product Database (DPD)
897
Drugs Product Database (DPD)
9750
ChemSpider
5833
BindingDB
18129
PDB
TYR
ZINC
ZINC000000266964
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11782
GenAtlas
TH
GeneCards
TH
GenBank Gene Database
Y00414
GenBank Protein Database
37127
UniProt Accession
TY3H_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:24249
GenAtlas
YARS2
GeneCards
YARS2
GenBank Gene Database
AF132939
GenBank Protein Database
4680649
UniProt Accession
SYYM_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12840
GenAtlas
YARS
GeneCards
YARS1
GenBank Gene Database
U40714
GenBank Protein Database
1184699
UniProt Accession
SYYC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:11573
GenAtlas
TAT
GeneCards
TAT
GenBank Gene Database
X52520
GenBank Protein Database
36713
UniProt Accession
ATTY_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:10923
GenAtlas
SLC16A2
GeneCards
SLC16A2
GenBank Gene Database
U05321
GenBank Protein Database
458255
UniProt Accession
MOT8_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:17027
GeneCards
SLC16A10
GenBank Gene Database
AB057445
GenBank Protein Database
18640047
UniProt Accession
MOT10_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72